Skip to content
Pharma Observatory a Scientist.com platform

Source-defined biomarker

Prognostic enrichment biomarker to identify NASH patients more likely to experience clinical endpoints such as progression to cirrhosis, hepatic decompensation events during the timeframe of a NASH clinical trial

This exact source name has not been reconciled to a broader biomarker identity.

Prognostic enrichment biomarker to identify NASH patients more likely to experience clinical endpoints such as progression to cirrhosis, hepatic decompensation events during the timeframe of a NASH clinical trial is a source-defined biomarker in the evidence tier "FDA qualification project". This page lists evidence by type: FDA biomarker qualification projects (1), each linked to its source.

Source-scoped identity
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

FDA companion diagnostic assertions Measured, none recorded FDA biomarker qualification projects 1recorded Assay-provider ledger Measured, none recorded

FDA qualification project

An FDA Biomarker Qualification Program project names this biomarker.

Get the Prognostic enrichment biomarker to identify NASH patients more likely to experience clinical endpoints such as progression to cirrhosis, hepatic decompensation events during the timeframe of a NASH clinical trial report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Source-level evidence only

Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.

FDA biomarker qualification projects (1)

Shown in this order: most recent snapshot first.

FDA biomarker qualification projects
Project DDT number Source status Submitter Biomarker role
Prognostic enrichment biomarker to identify NASH patients more likely to experience clinical endpoints such as progression to cirrhosis, hepatic decompensation events during the timeframe of a NASH clinical trial DDT-BMQ-000106 Project status: Under review IMI2: LITMUS Not assigned

Not on this page

Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and assay-provider ledger.

Browse all biomarker evidence pages